Shows
Proactive - Interviews for investorsTonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapyTonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce a major milestone for the company and for patients: TONMYA is now commercially available by prescription at pharmacies across the United States. TONMYA is a first-in-class, non-opioid analgesic designed specifically for adults with fibromyalgia and is taken once nightly at bedtime.
Dr. Lederman told Proactive that this marks a transformative moment for the estimated 10 million Americans living with fibromyalgia, a chronic condition characterized by widespread pain, sleep disturbance, fatigue, and impaired quality of life. TONMYA offers a novel therapeutic option that directly targets the condition’s co...
2025-11-2505 minProactive - Interviews for investorsTonix Pharmaceuticals teams up with MGH to advance Phase 2 trial of TNX-1500Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) CEO Dr. Seth Lederman talked with Proactive's Stephen Gunnion about the company's collaboration with Massachusetts General Hospital, affiliated with Harvard Medical School, to advance the clinical development of TNX-1500.
Lederman explained that the partnership supports an Investigator Initiated Phase 2 clinical trial focused on kidney transplant recipients. Study initiation is contingent on institutional review board (IRB) approval and FDA clearance of the investigator-initiated investigational new drug application (IND).
The study will assess TNX-1500, an anti-CD40 ligand monoclonal antibody, alongside a low-dose regimen of tacrolimus. The goal is to reduce or potentially eliminate the need for...
2025-11-1704 minProactive - Interviews for investorsTonix Pharmaceuticals doses first patient in MGH-Led FOCUS study of intranasal Oxytocin therapyTonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the first patient has been dosed in the investigator-initiated FOCUS study at Massachusetts General Hospital. The study is focused on adult patients with arginine-vasopressin deficiency (AVP-D)—a rare endocrine disorder formerly known as central diabetes insipidus—that is now understood to be linked to oxytocin deficiency and adverse mental health outcomes.
Dr. Lederman explained that oxytocin, commonly known as the “bonding hormone,” plays a critical role in regulating mood, social behavior, and emotional wellbeing. Emerging evidence suggests that individuals with AVP-D suffer from low oxytocin levels...
2025-10-2404 minProactive - Interviews for investorsTonix Pharmaceuticals advances TNX-2900 into Phase 2 trial for Prader-Willi SyndromeTonix Pharmaceuticals Holdings CEO Dr. Seth Lederman shared with Steve Darling from Proactive to announce a major milestone for the company’s rare disease pipeline: the advancement of its TNX-2900 program for the treatment of Prader-Willi syndrome into a Phase 2 clinical trial.
TNX-2900 is a proprietary magnesium-potentiated intranasal oxytocin formulation designed to improve receptor binding and reduce inconsistencies in receptor activity often observed with standard oxytocin dosing. The program has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). Importantly, these designations could make Tonix eligible for a transferable Priority Re...
2025-10-0803 minProactive - Interviews for investorsTonix advances TNX-102 SL for depression after positive FDA meeting boosts development pathTonix Pharmaceuticals Holdings CEO Dr. Seth Lederman shared with Steve Darling from Proactive to share a major milestone in the company’s clinical development pipeline — the successful completion of a Type B Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the potential development of TNX-102 SL for the treatment of major depressive disorder.
Lederman said the FDA provided positive and constructive feedback, giving Tonix the confidence to move forward with plans to submit a supplemental new drug application to expand the therapeutic indications of TNX-102 SL. The company’s approach is based on exploratory findings that s...
2025-09-2404 minProactive - Interviews for investorsTonix gains global rights to TNX-4800, developing one-dose seasonal protection for Lyme diseaseTonix Pharmaceuticals Holdings CEO Dr. Seth Lederman shared with Steve Darling from Proactive that the company has secured an exclusive worldwide in-licensing agreement for TNX-4800, a groundbreaking investigational therapy designed to provide seasonal protection against Lyme disease. The treatment is intended as a single subcutaneous dose administered in the spring to offer protection throughout the entire tick season, lasting into the fall.
Originally developed by researchers at UMass Chan Medical School, TNX-4800 is being licensed to Tonix to advance its development and commercialization. This strategic acquisition represents a significant milestone in the company’s mission to expand its infectious disease pi...
2025-09-2204 minProactive - Interviews for investorsTonix showcases Phase 3 data for FDA-approved Tonmya at PAINWEEK 2025, eyes launch next quarterTonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share that the company presented four scientific posters at the PAINWEEK 2025 conference in Las Vegas, Nevada, showcasing robust data from two pivotal Phase 3 trials of Tonmya® for the treatment of fibromyalgia.
The first study, RELIEF, was a 14-week randomized, double-blind, placebo-controlled trial, while the second, RESILIENT, served as a confirmatory efficacy and safety trial. Results across both studies demonstrated that Tonmya significantly reduced fibromyalgia-related pain while maintaining a favorable tolerability profile.
Unlike conventional pain therapies, Tonmya is designed to pharmacologically target nonrestorative sleep by antagonizing receptors that r...
2025-09-1205 min
Fibromyalgia Podcast®Tonmya™ For Fibromyalgia: A Long-Awaited New Medication with Dr. Seth LedermanHave you been hearing the buzz about the new medication approved for the treatment of fibromyalgia? Fibromyalgia can come with a myriad of symptoms that make everyday life more difficult. With the limited pharmaceutical options available, the addition of another FDA-approved medication is a ray of hope. Tonmya™ is the first medication approved for fibromyalgia in over 15 years, promising a new option for those of us with fibromyalgia. Today, Tami is joined by Dr. Seth Lederman, one of the co-founders of the company that developed Tonmya™, to talk about the journey from idea to FDA appr...
2025-09-0946 minProactive - Interviews for investorsTonix Pharmaceutical’s Tonmya approved: first fibromyalgia drug in 15 yearsTonix Pharmaceuticals CEO Seth Lederman talked with Proactive's Stephen Gunnion about the FDA approval of Tonmya, the first new fibromyalgia treatment in over 15 years.
Lederman described Tonmya as a "first in class medicine" with a different mechanism of action from the three currently approved drugs for fibromyalgia. The approval is the result of a 15-year development journey, during which the company took the product from concept to clinical trials and now to market authorisation.
Tonmya is indicated for the long-term treatment of fibromyalgia in adults, including geriatric patients and those with mild hepatic impairment. It is administered as a sublingual...
2025-08-1906 minProactive - Interviews for investorsTonix launches Move Fibro Forward campaign to support millions living with FibromyalgiaTonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to announce the launch of the “Move Fibro Forward” campaign by Tonix Medicines, Inc., the company’s commercial subsidiary.
This initiative aims to raise awareness, offer support, and bring greater visibility to the millions of individuals affected by fibromyalgia—a chronic and often misunderstood pain disorder that has seen no new FDA-approved treatments in more than 15 years. Fibromyalgia impacts an estimated 10 million adults in the U.S., with approximately 80% of those affected being women.
The condition is believed to result from amplified pain and sensory processing in the central...
2025-07-3005 minProactive - Interviews for investorsTonix targets August PDUFA date for Fibromyalgia drug candidate, advances mpox vaccine strategyTonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to discuss updates on two of the company’s key investigational therapies: TNX-801 and TNX-102 SL. Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Lederman shared recent findings on TNX-801, a recombinant horsepox-derived live-virus vaccine candidate for mpox and smallpox presented at the Vaccine Congress 2025 in Vienna.
The latest data demonstrate that TNX-801 delivers durable humoral and cellular immunity from a single dose, while remaining highly attenuated—replicating much times...
2025-07-2105 minProactive - Interviews for investorsTonix Pharmaceuticals joins Russell 3000 and 2000 indexes, expanding institutional visibilityTonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to announce a significant milestone for the company—its inclusion in the Russell 3000® Index, with automatic membership in the Russell 2000® Index, effective immediately. This development enhances Tonix’s visibility and credibility among institutional investors and fund managers worldwide.
The inclusion follows the annual reconstitution of the Russell U.S. indexes, which captures the 4,000 largest U.S.-based stocks as of April 30, ranked by total market capitalization. FTSE Russell, the global index provider, determines inclusion using objective, rules-based criteria, primarily market cap rankings and style attributes.
The Russell 3000® Index represe...
2025-07-0203 min
Drug Target Review PodcastOvercoming obstacles in personalised medicineIn this episode, we explore the key challenges hindering the widespread adoption of personalised medicine and discuss how overcoming these barriers could transform the future of healthcare. Featuring insights from Seth Lederman, co-founder, CEO, and Chairman of Tonix Pharmaceuticals, and Steve Gardner, CEO of Precision Life and Chair of the UK Bioindustry Association Genomics Board, this conversation addresses the critical issues shaping the field. Topics include the necessary adaptations in healthcare systems to support this shift, the ethical concerns surrounding patient data privacy and genetic information, and the groundbreaking advancements anticipated in the near future.
2024-12-1033 min
My Blog » demo20-download Pdf The 5 Star Group’s Guide To Marketing Your Practice Online: 5 Steps to Attract More Patients Faster, Easier, & With Less Effort by Seth Lederman full pagesLink To Download : https://recomendedbook.com/?book=1631640119 To Download or Read The 5 Star Group’s Guide To Marketing Your Practice Online: 5 Steps to Attract More Patients Faster, Easier, & With Less Effort by Seth Lederman Available versions: EPUB, PDF, MOBI, DOC, Kindle, Audiobook, etc. Reading The 5 Star Group’s Guide To Marketing Your Practice Online: 5 Steps […]
2024-10-0500 min
NewsRamp Health & Wellness PodcastInnovations in Healthcare: Obesity Management, Fibromyalgia Therapy, Spine Surgery Advancements, and Cancer Immunotherapy BreakthroughsToday's episode covers a range of innovative healthcare topics. Dr. Craig Primack discusses the impact of obesity and the effectiveness of GLP-1 injections for weight loss. Tonix Pharmaceuticals CEO Dr. Seth Lederman highlights the market opportunity for Tonmya in fibromyalgia management. Spine Surgeon Mark W. McFarland, DO, shares his experience with the first Intracept® Basivertebral Nerve Ablation procedures. Lastly, Elicio Therapeutics presents promising data from their AMPLIFY-7P Phase 1a Study of ELI-002 7P in patients with mKRAS-driven solid tumors.
2024-06-1105 min
Is Franchising Right For You?Franchise Consultancy with Seth Lederman of FrannexusIs Franchising Right for You? With Richard Morgin, Episode 12 In this episode of Is Franchising Right for You?, Rick Morgin speaks with Seth Lederman, Founder of Frannexus. Frannexus facilitates franchise ownership for investment diversification or as a career transition alternative.Tune in to the episode to hear about:
How and why Seth’s career shifted from chiropractic care to franchising consultancy
Seth’s process when working with franchising clients
The challenges of franchising
Learn more about Seth Lederman:Connect with Seth on LinkedIn:https://www.linkedin.com/in/sethledermanfrannexusConnect with Franne...
2024-03-2932 min
The ExecutiveEmbracing Ambiguity: Dr. Seth Lederman, CEO & Chairman of Tonix PharmaceuticalsDr. Seth Lederman, CEO and Chairman of Tonix Pharmaceuticals, shares insights into his journey from medical practice to pharmaceutical entrepreneurship. From his early days combating the AIDS epidemic to specializing in rheumatology and fibromyalgia research, Dr. Lederman discusses the lessons learned from founding and leading Tonix Pharmaceuticals.
Dr. Lederman offers valuable insights into the dynamics of drug development and commercialization. He also shares his perspective as a seasoned CEO, providing actionable advice on effective leadership and fostering a culture of innovation within the company. With the impending launch of Tanmaya, Tonix's pioneering product for fibromyalgia management...
2024-03-2235 minFibromyalgia Podcast®New Medications for Fibromyalgia w/ Dr. Seth Lederman: Ask the CoachOne of the questions Tami gets most often is, "When are we going to have new fibromyalgia treatment options?" With only three FDA-approved fibromyalgia medications, many of us are on the alert for new options to address our symptoms better. To answer that question, Tami invited Dr. Seth Lederman, CEO and founder of Tonix, to talk about the fibromyalgia medication currently in phase three trials, TNX-102 SL. Dr. Lederman has dedicated his career to fibromyalgia research and has worked on this drug for almost 25 years. Today he's sharing all the details about how TNX-102 SL could help...
2023-06-2042 min
RARECastA Nasal Spray to Curb Excessive Eating in Prader-WilliParder-Willi syndrome is a rare, genetic disease that is characterized, in part, by hyperphagia—an intense and insatiable hunger. People with the condition are driven to constantly eat and seek out food. The syndrome is associated with severe obesity and obesity-related mortality. Tonix Pharmaceuticals is developing an experimental oxytocin nasal spray to treat hyperphagia in people with Prader-Willi syndrome. The approach, to date, has shown promise in animal models. We spoke to Seth Lederman, CEO of Tonix, about Prader-Willi syndrome, the unmet need for treatments, and why he believes an oxytocin nasal spray has potential to treat the condition.
2023-05-1122 min
BioTech Nation ... with Dr. Moira GunnLong Covid related to Fibromyalgia? Dr. Seth Lederman, Tonix PharmaceuticalsDr. Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, tells us that Long Covid may be related to Fibromyalgia. Now recruiting in advanced Human Clinical Trials ... www.tonixpharma.com
2023-02-2333 min
Founders Keepers#33 Dr Seth Lederman - Vaccines and drug repurposing in biodefense and PTSD with Tonix PharmaceuticalsTonix Pharmaceuticals is a pharmaceutical company based in New Jersey focused on repurposing drugs for neurological conditions and developing vaccines for COVID-19, smallpox and other biodefense projects. More recently, the FDA awarded one of its drug candidates, TNX -102 SL, with breakthrough therapy designation for the treatment of post-traumatic stress disorder following studies in the US military.
Seth is an enormously accomplished physician, scientist and entrepreneur. In particular prior to co-founding Tonix, where he is now the current President and Chairman, he worked as an assistant professor at Columbia University on the team that discovered the CD40-Ligand (CD154) and e...
2023-02-0332 min
Business Of BiotechWhat's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D.We love to hear from our listeners. Send us a message. As COVID-19 cases climb yet again, the Business of Biotech catches up with Tonix Pharmaceuticals CEO Seth Lederman, M.D. for a conversation on his company's multi-pronged strategy to advance vaccine and therapeutic candidates to address the disease and its variants. In addition to sharing on his journey from academia to industry, Dr. Lederman discusses his company's approach to grabbing its share of the highly competitive, and highly lucrative, vaccine market.Access this and hundreds of episodes of the Business of Biotech videocast
2022-05-231h 06
Is Breakfast Included?35 - Detrick LowmanOn today’s show I catch up with my old friend and fellow tech, Detrick Lowman. Detrick is the long-time stage manager & drum tech for the band, The Roots. He’s also the Senior Music Coordinator for Late Night with Seth Myers - which makes him one of the busiest guys in the business! Despite working two jobs, he made time to chat with me and break down a typical day in his life. We shared a couple stories and he let us know that it’s okay to fly to Italy and back in 52 hours!
in...
2021-11-0528 min
The Best Of BioTech IQ#28 Vaccine Durability, Diversified Pipeline, Winning Strategy - Seth Lederman, MD - CEO Tonix PharmaceuticalsSeth Lederman is the CEO of Tonix Pharmaceuticals and a physician scientist with a two decades of research experience. Prior to becoming an entrepreneur, he was an Associate Professor at Columbia University. Dr. Lederman’s groundbreaking research led to the discovery of the CD-40 ligand and its role in T cell helper function. Currently, Dr. Lederman oversees Tonix Pharmaceuticals and its diverse programs that are aimed to develop therapeutics for chronic CNS and immunologic conditions, that include indications like fibromyalgia, Covid-19 and Long Covid, amongst others. Dr. Lederman earned an AB from Princeton University in Chemistry and an MD from Co...
2021-10-0156 min
Conversations in HealthcareBringing new medicines to market despite subjective endpointsIn this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals. Seth and Mike explored the two programs Tonix are currently developing in pain and psychiatry, areas where many larger companies have turned their back due to subjective endpoints. Tonix believes they have developed invaluable expertise to counter these challenges and Seth explains that the difficulty of the endpoints, will be compensated by the importance of bringing new medicines to market that will be significant to the pharmacopeia. Tonix is...
2020-11-1831 min
Biotech 2050 Podcast32. Vaccine origins to combat COVID-19, Seth Lederman, Co-Founder/CEO, Tonix PharmaceuticalsSeth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance.
Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Dir...
2020-09-3018 min
The Comedians of WrestlingReturn of The ChampJabroniacs and #AdultWrestlingFans!
Dan and Newman take a second to thank everyone for making #cOwMania such a success! Dan and Lederman squash the beef! Dan dissects why this Wrestlemania was an "almost"! Dan gushed over Seth Rollins ring gear! Plus we explain why the length of Wrestlemania isn't a problem!
Check out Patreon.com/ComediansOfWrestling for bonus episodes!
Official cOw merch available at prowrestlingtees.com/comediansofwrestling
Join the cOw Facebook Community: www.facebook.com/groups/1097358233676577/
Got a hot take you wanna cash-in? Leave a voicemail at (316) 530 2429
2019-04-111h 54The Comedians of WrestlingAlex Newman is MissingJABRONIACS and #AdultWrestlingFans!
Alex Newman doesn’t show up for the pod and he’s not answering our calls! Dan loves that the women weren’t given the Wrestlemania main event, they earned it! Adam Lederman’s paralegal joins us in studio for a #cOwMania contract signing gone wrong! Dan discusses Charlotte's big win and explains why he is more into Ronda than Becky! Sarah Claspell stops by to talk about dudes bodies with Dan! And Dan breaksdown why he thinks Becky, Kofi and Seth should all win at Wrestlemania 35!
Tickets to CowMania Sat 4/6 NYC 4PM, Available here: http://tiny.cc/cOwMa...
2019-03-281h 48
Pharmaceutical ExecutiveEpisode 27: Sensitive Topics in PharmaPharm Exec editors talk with Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals about how to navigate creating drugs for conditions such as PTSD and AIDS, running a business, and academia.
2019-03-1523 min
TechNation Health PodcastEpisode 17-39 It’s not just any plaque that brings about Alzheimer’sOn this week’s Tech Nation Health, Moira speaks with …
Dr. Seth Lederman from Tonix Pharmaceuticals about military-related PTSD. Their drug has been fast-tracked by the FDA. Then on Tech Nation Health, Chief Correspondent Daniel Kraft with Jordan Amadio about the emergent technology in the field of neurosurgery, and Dr. Elliot Goldstein from ProMIS Neurosciences the particular kind of plaque that brings about Alzheimer’s.
2017-10-0525 min
World Health NewsSegment: Dr. Samadi is joined by Dr. Seth Lederman to discuss fibromyalgiaSegment: Dr. Samadi is joined by Dr. Seth Lederman to discuss fibromyalgia by Dr. Samadi
2015-06-1409 min
School for Startups Radio11.03 Franchising w Seth Lederman & Fixing your Credit w Shindy ChenNovember 3, 2014 Franchising w Seth Lederman & Fixing your Credit w Shindy Chen
2014-11-0354 min